| Literature DB >> 26283913 |
Chao-Hui Yang1, Thomas Schrepfer2, Jochen Schacht2.
Abstract
Understanding underlying pathological mechanisms is prerequisite for a sensible design of protective therapies against hearing loss. The triad of age-related, noise-generated, and drug-induced hearing loss displays intriguing similarities in some cellular responses of cochlear sensory cells such as a potential involvement of reactive oxygen species (ROS) and apoptotic and necrotic cell death. On the other hand, detailed studies have revealed that molecular pathways are considerably complex and, importantly, it has become clear that pharmacological protection successful against one form of hearing loss will not necessarily protect against another. This review will summarize pathological and pathophysiological features of age-related hearing impairment (ARHI) in human and animal models and address selected aspects of the commonality (or lack thereof) of cellular responses in ARHI to drugs and noise.Entities:
Keywords: acquired hearing loss; aminoglycoside antibiotics; noise trauma; ototoxicity; presbycusis
Year: 2015 PMID: 26283913 PMCID: PMC4515558 DOI: 10.3389/fncel.2015.00276
Source DB: PubMed Journal: Front Cell Neurosci ISSN: 1662-5102 Impact factor: 5.505
Selected features of acquired hearing loss.
| Age | Drugs | Noise | |
|---|---|---|---|
| Organ of Corti | Loss of hair cells in sensorineural hearing loss | Loss of (primarily outer) hair cells | Dislocation of tectorial membrane from stereocilia; breaking of tip links; loss of hair cells |
| Stria vascularis (and spiral ligament) | Compromised structure and possibly function in some forms of hearing loss | Aminoglycosides: endolymphatic potential (EP) unaffected Cisplatin: EP may be decreased | May reduce EP; loss of fibrocytes |
| Spiral ganglion and auditory nerve | Reduced in sensorineural hearing loss; loss of synaptic connections | Loss considered mostly secondary; loss of synaptic connections possible | Loss of synaptic connections |
| Evidence | Causal relation largely not supported | + | + |
| Likely sources | Mitochondria | Aminoglycosides: non-enzymatic; mitochondria; NADPH oxidase Cisplatin: mitochondria, NADPH oxidase | mitochondria; NADPH oxidase; calcium influx may cause oxidative stress |
| mtDNA mutations might impair auditory function; specific mutations correlate with presbycusis in human | Aminoglycosides: Bind to mtRNA and impair mitochondrial protein synthesis and function; inhibition of the electron transport chain | Reduced blood flow may impair oxidative phosphorylation | |
| Apoptosis | + | + | + |
| Necrosis | + | Aminoglycosides: + Cisplatin: ? | + |
| MAPK pathway | + | Aminoglycosides: + Cisplatin: JNK ? | + |
| Caspase-dependent | ? | Evidence mostly from | + |
| Caspase-independent | ? | + | |
| Homeostasis (e.g., Prx3) | + | + | + |
| NF-κB | Not determined | Aminoglycosides: + | + |
| PI3-kinase | + | Aminoglycosides: + | ? |
| Heat shock proteins | + | + | + |
| Nutritional supplements | Inconsistent in animals Inconclusive evidence in clinical trials and epidemiological studies | Aminoglycosides: Consistent protection in animals; successful clinical trials. Cisplatin: success in animal studies | Mostly protective in animal studies Inconclusive in clinical or field trials, which are largely of temporary hearing loss |
+, supporting evidence exists; ?, not known or inconclusive. For drug-induced hearing loss, preference was given to results from studies in vivo or with cochlear tissues in vitro; for age-related hearing loss, results from confounded models (See text: mice with Cdh23 mutations or catastrophic mitochondrial mutations) were de-emphasized.